Acorda Therapeutics (ACOR) Tops Q4 EPS by 6c
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
EPS Growth %: -139.7%
Financial Fact:
Loss before taxes: -10.01M
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: -139.7%
Financial Fact:
Loss before taxes: -10.01M
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $130.9 million versus the consensus estimate of $128.24 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
- Nokia slightly down as Q1 profit growth fails to meet consensus; outlook unchanged
- First Industrial Realty (FR) Tops Q1 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
